Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Trimebutine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A known ✓ | Q03164 | 3/20 | 1.00 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.90 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.90 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.90 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.90 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.90 |
| ▸ | MTOR known ✓ | P42345 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.90 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.90 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimebutine SCHEMBL67225 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| Trimebutine SCHEMBL28274910 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| Trimebutine SCHEMBL1652810 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| Trimebutine SCHEMBL25705 | 0.95 | OPRM1 (1.00) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| Trimebutine SCHEMBL14273976 | 0.95 | OPRM1 (1.00) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| Trimebutine SCHEMBL7428847 | 0.94 | OPRM1 (0.98) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| SCHEMBL16522145 | 0.88 | OPRM1 (0.88) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| SCHEMBL14317655 | 0.86 | OPRM1 (0.83) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| Trimebutine SCHEMBL2017641 | 0.86 | ALDH1A1 (0.74) | ALDH1A1MAPTKMT2AOPRM1OPRD1 | |
| Maleic Acid SCHEMBL9832430 | 0.85 | ALDH1A1 (0.74) | ALDH1A1MAPTKMT2AOPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748489-B2 | Solid pharmaceutical composition containing a combination of an intestinal motility regulating agent and an antiflatulent | Procaps SAS (CO) | 2014-06-10 | — | — | US | disclosed |
| US-20080038336-A1 | Solid pharmaceutical composition containing a combination of an intestinal motility regulating agent and an antiflatulent | ESQUEA MARTA LUZ TORRES | 2008-02-14 | — | — | US | disclosed |
| US-7041704-B2 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| EP-1596844-A2 | USE OF SODIUM CHANNEL MODULATORS FOR TREATING GASTROINTESTINAL TRACT DISORDERS | Dynogen Pharmaceuticals Inc. (US) | 2005-11-23 | — | — | EP | disclosed |
| EP-1589959-A2 | METHODS OF TREATING LOWER URINARY TRACT DISORDERS USING SODIUM CHANNEL MODULATORS | Dynogen Pharmaceuticals Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050203190-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| US-20050107353-A1 | Methods of treating lower urinary tract disorders using losigamone | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-05-19 | — | — | US | disclosed |
| US-20040213842-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | disclosed |
| US-20040209960-A1 | Methods of treating lower urinary tract disorders using sodium channell modulators | DYNOGEN PHARMACEUTICALS, INC. | 2004-10-21 | — | — | US | disclosed |
| WO-2004066990-A2 | METHODS OF TREATING LOWER URINARY TRACT DISORDERS USING SODIUM CHANNEL MODULATORS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| EP-0298703-B1 | A THIOPHENE DERIVATIVE AND PROCESS FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 1991-03-06 | — | — | EP | disclosed |
| US-4946862-A | Thiophene derivative and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1990-08-07 | — | — | US | disclosed |
| US-4857543-A | TREATMENT OF GASTROINTESTINAL DISORDERS | TANABE SEIYAKU CO., LTD. (JP) | 1989-08-15 | — | — | US | disclosed |
| EP-0298703-A1 | A thiophene derivative and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1989-01-11 | — | — | EP | disclosed |
| EP-0297782-A1 | A thiophene derivative and process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1989-01-04 | — | — | EP | disclosed |
| US-4542042-A | Process for preparing free-flowing ethylcellulose microcapsules | TANABE SEIYAKU CO., LTD. (JP) | 1985-09-17 | — | — | US | disclosed |
| US-4486471-A | WATER-INSOLUBLE, ACID-SOLUBLE POLYMER | TANABE SEIYAKU CO., LTD. (JP) | 1984-12-04 | — | — | US | disclosed |
| US-4443497-A | DISSOLVING, COATING, SOLVENTS, POLYMER, ETHYL CELLULOSE, ANTICOAGULANTS, DRUGS | TANABE SEIYAKU CO., LTD. (JP) | 1984-04-17 | — | — | US | disclosed |
| EP-0099109-A1 | Process for preparing free-flowing ethylcellulose microcapsules | Tanabe Seiyaku Co., Ltd. (JP) | 1984-01-25 | — | — | EP | disclosed |
| US-4389331-A | Process for preparing pharmaceutically active compound-containing microcapsules | TANABE SEIYAKU CO., LTD. (JP) | 1983-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203190-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | SLC10A2, TRPV1, VIPR2 | KMT2A 1957/4885MEN1 3421/4885CHRM2 1157/4885 |
| US-20040213842-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | SLC10A2, VIPR2, TRPV1 | KMT2A 1939/4885MEN1 3469/4885CHRM2 1101/4885 |
| US-20050107353-A1 | Methods of treating lower urinary tract disorders using losigamone | LPXN, TRPM5, SLC10A2 | KMT2A 2750/4885MEN1 3365/4885CHRM2 1051/4885 |
| US-20040209960-A1 | Methods of treating lower urinary tract disorders using sodium channell modulators | CACNA1G, CACNA1D, CACNA1B | KMT2A 2324/4885MEN1 4234/4885CHRM2 1011/4885 |
| US-20080038336-A1 | Solid pharmaceutical composition containing a combination of an intestinal motility regulating agent and an antiflatulent | MLNR, TRIM33, OPRD1 | KMT2A 2062/4885MEN1 4048/4885CHRM2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.